$193.76
Closed
-(-)

At close

Financial advisor consultation illustration
Get professional financial guidance

Schedule your free first call with a financial advisor on CUSP Wealth
*T&Cs apply

About

Illumina, Inc. engages in the development, manufacturing, and marketing of life science tools and integrated systems for large-scale analysis of genetic variation and function. The company is headquartered in San Diego, California and currently employs 8,600 full-time employees. The company went IPO on 2000-06-28. The firm's products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. Its comprehensive line of products addresses the scale of experimentation and breadth of functional analysis to advance disease research, drug development, and the development of molecular tests. The company also specializes in data-driven proteomics technology. Its products include instruments, kits and reagents, selection tools, and software and analysis. Its services include sequencing services, microarray services, proactive instrument monitoring, and instrument services and training.
Country

US

CEO

Mr. Jacob Thaysen

IPO date

2000

Employees

8,600

ISIN

US4523271090

Key stats

Open

$194.00

Volume

1.73M

Market cap

$28.42B

Prev. close

$193.76

Impl / hst vl

-

Open interest

$0.00

$193.76

Day’s Range

$194.00

$112.65

52W Range

$196.66

Valuation

44
Valuation score
Fairly Valued
P/E
33.09
P/S
6.42
P/B
10.55
Current ratio
1.75
Debt / Equity
0.34
ROE
33.99%
Gross margin
66.09%
Income growth
-59.88%
FCF growth
-5.64

Analysts estimates

Consensus rating
Buy

The average rating from top 10 analysts indicates that stock is expected to perform in line with the market

Str. Sell
Sell
Hold
Buy
Str. Buy
Avg. price target
$153.01
The top 23 analysts forecasts that 12-month price may decrease by 21.03%, with a low of $95.95 and a high of $210.00
$95.95
Low
$153.01
Avg
$210.00
High
Current price

Earnings

Q1 ‘26 revenue
$1.09B
Q1 ‘26 net income
$134.00M
Revenue
Net income
Previous EPS
$1.15
Estimate EPS
$1.25
Actual EPS
Estimate EPS
Financial advisor consultation illustration
Get professional financial guidance

Schedule your free first call with a financial advisor on CUSP Wealth
*T&Cs apply